Panitumumab

The FDA approved two oncology regimens on Jan. 16.

MADRID — Sotorasib plus panitumumab prolonged PFS compared with standard of care for patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer, study results presented at ESMO Congress showed.

The addition of panitumumab vs. bevacizumab to standard first-line chemotherapy significantly extended OS for certain patients with RAS wild-type metastatic colorectal cancer, according to data published in JAMA.

In this video, Smitha S. Krishnamurthi, MD, discussed the results of the IMPROVE trial, which she said showed significant results in terms of the length of PFS on treatment with an intermittent panitumumab plus FOLFIRI strategy.

In this video, Michael Cecchini, MD, discussed a late-breaking abstract evaluating FOLFOXIRI plus panitumumab vs. mFOLFOX6 plus panitumumab as initial treatment of unresectable RAS and BRAF wild-type metastatic colorectal cancer.

In this video, Howard S. Hochster, MD, FACP, discusses a late-breaking abstract on the phase 3 PARADIGM trial, which looked at panitumumab vs. bevacizumab as first-line treatment in patients with RAS wild-type metastatic colorectal cancer.

CHICAGO — The addition of panitumumab vs. bevacizumab to standard doublet chemotherapy significantly extended survival among patients with RAS wild-type and left-sided metastatic colorectal cancer, according to study results.

Maintenance therapy with 5-fluoruracil/leucovorin plus panitumumab better maintained wildtype metastatic colorectal cancer than 5-fluoruracil/leucovorin alone, according to data from a study presented at ASCO21.

Liquid biopsy-driven rechallenge with panitumumab led to objective responses in about one-third of patients with metastatic colorectal cancer, according to results of the phase 2 CHRONOS study presented at the virtual ASCO Annual Meeting.

A recent study presented at the Gastrointestinal Cancers Symposium revealed low health-related quality of life scores among young adult survivors of colorectal cancer. It was the top story in hematology/oncology last week.